Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

UCB Pharma Limited
208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 15/07/2011
SPC Parvolex 200 mg/ml Concentrate for Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 15/07/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   01-Jun-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Correction of section 4.4
Excipient warning for sodium content added. 
Updated on 27/01/2011 and displayed until 15/07/2011
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC:   01-Jun-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 1: Update of name to: Parvolex 200 mg/ml Concentrate for Solution for Infusion
Updated on 05/05/2010 and displayed until 27/01/2011
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
Date of revision of text on the SPC:   01-Mar-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 2: correction of typo - Sodium content 3.22.6 mg.
Updated on 07/04/2010 and displayed until 05/05/2010
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   18-Mar-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.4 - information on haemostatic parameters and caution in children because of risk of fluid overload.
Section 4.8 - additional side effect of prothrombin time abnormal
Updated on 04/03/2010 and displayed until 07/04/2010
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   01-Feb-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 2: Addition of sodium content
Section 4.4: Sodium content warning added
Updated on 15/09/2005 and displayed until 04/03/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 24/01/2003 and displayed until 15/09/2005
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 6.1 - List of Excipients
Updated on 05/10/2001 and displayed until 24/01/2003
Reasons for adding or updating:
  • New SPC for new product
Updated on 25/08/2001 and displayed until 05/10/2001
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 06/09/1999 and displayed until 25/08/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  acetylcysteine